Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.822045
Title: Drug action and resistance in malaria parasites : experimental genetics models and biochemical features of fast acting novel antimalarials
Author: Simwela, Nelson Victor
ISNI:       0000 0005 0286 7254
Awarding Body: University of Glasgow
Current Institution: University of Glasgow
Date of Award: 2020
Availability of Full Text:
Access from EThOS:
Access from Institution:
Abstract:
Resistance to antimalarial drugs inevitably follows their deployment in malaria endemic parts of the world. For instance, current malaria control efforts which significantly rely on artemisinin combination therapies (ACTs) are being threatened by the emergence of resistance to artemisinins and ACTs. Understanding the role of genetic determinants of artemisinin resistance is therefore important for implementation of mitigation strategies. Moreover, elucidating the mode of action for drugs that are in advanced stages of development is specifically critical as drug resistance mechanisms can be prospectively predicted and possible means of surveillance put in place. In the present work, CRISPR-Cas9 genome editing has been used to engineer candidate artemisinin resistance mutations (Kelch13 and UBP-1) in the rodent malaria parasite Plasmodium berghei. The role of these mutations in mediating artemisinin (and chloroquine) resistance under both in vitro and in vivo conditions has been assessed which up until now, has either remained un-validated (UBP-1) or debated (Kelch13, under in vivo conditions) in human infecting Plasmodium falciparum. The results have provided an in vivo model for understanding and validating artemisinin resistance phenotypes which just like their Plasmodium falciparum equivalents do not just mediate resistance phenotypes, but also carry accompanying fitness costs. In addition to the above findings, biochemical and drug inhibition studies have been carried out to demonstrate that small molecule inhibitors targeting ubiquitin hydrolases (to which UBP-1 is a class member) display activity in human and rodent infecting malaria parasites in vitro and in vivo. These inhibitors also show evidence of ability to potentiate artemisinin action which can be exploited to overcome the emerging resistance as combination partner drugs. Untargeted metabolomic screens have also been used to characterize the mode of action of lead antimalarial drug candidates that are emerging from the Novartis Institute of Tropical Diseases drug discovery pipeline. A common biochemical and metabolic profile of these compounds which display a very fast parasite killing rate is presented and can hopefully be used to identify compounds that can achieve a similar feat. Moreover, these profiles have pointed to possible mode of action for novel drugs whose mechanistic mode of parasite killing is still unknown or disputed.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.822045  DOI: Not available
Keywords: QR Microbiology
Share: